Table 5.
Subgroup Analysis of Percentage Change From Baseline to W24 According to Baseline Quartiles for LDL-C and Lp(a) (ITT Population)
| Baseline Lipid < Q1a | Q1 ≤ Baseline Lipid < Median | Median ≤ Baseline Lipid < Q3a | Q3 ≤ Baseline Lipid | |||||
|---|---|---|---|---|---|---|---|---|
| Alirocumab | Placebo | Alirocumab | Placebo | Alirocumab | Placebo | Alirocumab | Placebo | |
| LDL-C | ||||||||
| No. | 17 | 14 | 30 | 11 | 26 | 10 | 22 | 15 |
| Baseline, mean (SD), mg/dL | 72.8 (6.7) | 67.7 (6.1) | 89.1 (6.1) | 89.5 (7.0) | 112.8 (6.3) | 111.7 (6.5) | 148.3 (21.7) | 151.7 (20.4) |
| W24 change from baseline, LS mean (SE), % | −48.2 (8.7) | 19.3 (10.0) | −58.6 (4.0) | −3.3 (6.7) | −49.4 (6.5) | 10.7 (10.0) | −64.6 (4.5) | −9.5 (5.4) |
| Difference (SE) vs placebo | −67.6 (13.8) | −55.3 (7.8) | −60.1 (11.9) | −55.1 (7.1) | ||||
| Lp(a) | ||||||||
| No. | 22 | 10 | 22 | 14 | 20 | 12 | 24 | 12 |
| Baseline, mean (SD), mg/dL | 2.9 (1.5) | 2.9 (1.5) | 10.9 (4.2) | 10.8 (4.2) | 35.0 (8.1) | 39.4 (13.6) | 98.9 (46.6) | 107.0 (36.5) |
| W24 change from baseline, combined estimate for mean (SE), % | −5.3 (7.7) | −3.7 (12.3) | −36.5 (7.6) | 26.9 (9.4) | −26.7 (5.8) | 26.2 (7.7) | −11.0 (3.6) | 5.8 (4.9) |
| Difference (SE) vs placebo | −1.6 (14.6) | −63.3 (12.1) | −52.9 (9.9) | −16.7 (6.1) | ||||
Abbreviations: ITT, intention to treat; LS, least squares; Q, quartile.
a
Q1, median, and Q3 are quartiles of baseline lipid value.